Table 6.
Results of the base case cost-effectiveness analysis (year 2010 values) from the German hospital perspective (standard errors in parentheses)
| Type of surgery | Costs (€) | Incremental costs (€) | VTE events per person | Incremental effect (events avoided) | ICER (€ per event avoided) |
|---|---|---|---|---|---|
| THR |
|
|
|
|
|
| Rivaroxaban |
33.8 (3.3) |
31.8 (3.4) |
0.005 (0.002) |
0.007 (0.005) |
1,564 |
| Enoxaparin |
2.05 (0.7) |
|
0.012 (0.005) |
|
|
| TKR |
|
|
|
|
|
| Rivaroxaban |
38.8 (3.9) |
20.6 (5.6) |
0.014 (0.005) |
0.020 (0.007) |
1,014 |
| Enoxaparin | 18.1 (4.3) | 0.035 (0.009) |
THR = total hip replacement, TKR = total knee replacement, VTE = venous thromboembolism, ICER = incremental cost-effectiveness ratio.